NewEdge Wealth LLC Has $1.06 Million Stock Holdings in Cencora, Inc. $COR

NewEdge Wealth LLC raised its position in Cencora, Inc. (NYSE:COR) by 86.4% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 3,384 shares of the company’s stock after acquiring an additional 1,569 shares during the period. NewEdge Wealth LLC’s holdings in Cencora were worth $1,058,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in COR. Essex Financial Services Inc. boosted its holdings in Cencora by 44.1% during the third quarter. Essex Financial Services Inc. now owns 1,141 shares of the company’s stock worth $357,000 after purchasing an additional 349 shares during the last quarter. Syon Capital LLC boosted its stake in shares of Cencora by 13.3% during the 3rd quarter. Syon Capital LLC now owns 3,925 shares of the company’s stock worth $1,227,000 after buying an additional 462 shares during the last quarter. Advisors Capital Management LLC grew its holdings in shares of Cencora by 2.7% in the 3rd quarter. Advisors Capital Management LLC now owns 2,883 shares of the company’s stock valued at $901,000 after acquiring an additional 75 shares in the last quarter. NEOS Investment Management LLC grew its holdings in shares of Cencora by 97.5% in the 3rd quarter. NEOS Investment Management LLC now owns 18,007 shares of the company’s stock valued at $5,628,000 after acquiring an additional 8,890 shares in the last quarter. Finally, Zions Bancorporation National Association UT increased its position in shares of Cencora by 50.8% in the third quarter. Zions Bancorporation National Association UT now owns 840 shares of the company’s stock valued at $263,000 after acquiring an additional 283 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Cencora Price Performance

NYSE:COR opened at $360.70 on Monday. The company has a market cap of $70.17 billion, a P/E ratio of 43.35, a P/E/G ratio of 1.68 and a beta of 0.68. The firm’s fifty day moving average price is $349.41 and its two-hundred day moving average price is $331.39. Cencora, Inc. has a one year low of $240.72 and a one year high of $377.54. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.04. The firm had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business’s revenue was up 5.5% on a year-over-year basis. During the same period in the prior year, the firm earned $3.73 EPS. Equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Shareholders of record on Friday, February 13th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Cencora’s dividend payout ratio is currently 28.85%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on COR. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Wells Fargo & Company increased their price objective on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Weiss Ratings raised shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. JPMorgan Chase & Co. upped their price target on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Finally, Robert W. Baird set a $415.00 price objective on shares of Cencora in a research report on Tuesday, January 13th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and an average price target of $399.00.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. This trade represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the transaction, the executive vice president owned 23,891 shares in the company, valued at $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 15,220 shares of company stock valued at $5,282,867. 0.38% of the stock is currently owned by corporate insiders.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.